• 1. Cooperative interplay between a flexible PNN-Ru(ii) complex and a NaBH4 additive in the efficient catalytic hydrogenation of esters
  Zheng Wang,Xiangyang Chen,Bo Liu,Qing-bin Liu,Gregory A. Solan,Xinzheng Yang,Wen-Hua Sun Catal. Sci. Technol. 2017 7 1297
• 2. La(CH2C6H4NMe2-o)3-catalyzed reduction of esters to alcohols with pinacolborane
  Fangcao Zhang,Mingliang Gong,Hongzhen Xie,Yunjie Luo New J. Chem. 2021 45 17654
• 3. Amidation of unactivated ester derivatives mediated by trifluoroethanol
  Christopher G. McPherson,Nicola Caldwell,Craig Jamieson,Iain Simpson,Allan J. B. Watson Org. Biomol. Chem. 2017 15 3507
• 4. Oxalic acid as the in situ carbon monoxide generator in palladium-catalyzed hydroxycarbonylation of arylhalides
  Changdong Shao,Ailan Lu,Xiaoling Wang,Bo Zhou,Xiaohong Guan,Yanghui Zhang Org. Biomol. Chem. 2017 15 5033
• 5. Efficient and convenient oxidation of aldehydes and ketones to carboxylic acids and esters with H2O2 catalyzed by Co4HP2Mo15V3O62 in ionic liquid [TEBSA][BF4]
  Yu-Lin Hu,De-Jiang Li,Dong-Sheng Li RSC Adv. 2015 5 24936

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in the Application of Methyl 4-(trifluoromethyl)benzoate (CAS: 2967-66-0) in Chemical Biology and Pharmaceutical Research

Methyl 4-(trifluoromethyl)benzoate (CAS: 2967-66-0) is a key intermediate in the synthesis of various bioactive molecules and pharmaceuticals. Recent studies have highlighted its versatility in medicinal chemistry, particularly in the development of trifluoromethyl-containing compounds, which are known for their enhanced metabolic stability and bioavailability. This research briefing provides an overview of the latest advancements involving this compound, focusing on its synthetic applications, mechanistic insights, and potential therapeutic implications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of Methyl 4-(trifluoromethyl)benzoate as a precursor in the synthesis of novel kinase inhibitors. The trifluoromethyl group was found to significantly improve the binding affinity of these inhibitors to their target proteins, offering new avenues for the treatment of cancer and inflammatory diseases. The study employed advanced computational modeling and X-ray crystallography to elucidate the structural basis of these interactions, providing valuable insights for future drug design.

In another significant development, researchers at a leading pharmaceutical company utilized Methyl 4-(trifluoromethyl)benzoate to develop a series of antiviral agents targeting RNA-dependent RNA polymerase (RdRp). The incorporation of the trifluoromethyl group was critical in enhancing the compounds' resistance to enzymatic degradation, as reported in a 2024 Nature Communications article. These findings underscore the compound's potential in addressing emerging viral threats, including those posed by RNA viruses.

Beyond its therapeutic applications, Methyl 4-(trifluoromethyl)benzoate has also been explored in chemical biology for probing enzyme mechanisms. A recent ACS Chemical Biology study (2024) detailed its use as a mechanistic probe in studying cytochrome P450 enzymes, revealing novel aspects of substrate recognition and catalysis. Such applications highlight the compound's dual role as both a synthetic building block and a tool for fundamental research.

Looking ahead, the continued exploration of Methyl 4-(trifluoromethyl)benzoate is expected to yield further innovations in drug discovery and chemical biology. Its unique physicochemical properties, combined with the growing demand for fluorinated pharmaceuticals, position it as a compound of enduring interest to researchers. Future studies may focus on optimizing its synthetic routes and expanding its applications in targeted therapies and diagnostic agents.

• 26107-80-2(Methyl 3,5-bis(trifluoromethyl)benzoate)
• 124061-53-6(Benzoic acid, 3-(trifluoromethyl)-, [3-(trifluoromethyl)phenyl]methyl ester)
• 2557-13-3(Methyl 3-(trifluoromethyl)benzoate)
• 96617-71-9(Ethyl 3,5-bis(trifluoromethyl)benzoate)
• 651735-47-6(Benzoic acid, 4-(trifluoromethyl)-, [4-(trifluoromethyl)phenyl]methyl ester)
• 76783-59-0(Ethyl 3-(trifluoromethyl)benzoate)
• 583-02-8(Ethyl 4-(trifluoromethyl)benzoate)
• 31083-14-4(Aceticacid, 2,2,2-trifluoro-, 4-ethylphenyl ester)
• 444915-76-8(Methyl 4-(difluoromethyl)benzoate)
• 116419-94-4(Methyl 4-methyl-3-(trifluoromethyl)benzoate)